Jane Street’s Actuate Therapeutics ACTU Stock Holding History

Jane Street’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,625	Closed	-$102K	–	13288
2025 Q4	$102K	Buy	+16,625	New	+$114K	﹤0.01%	10182

Other funds holding ACTU

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

PVM

Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's ACTU Position: Q1 2026 in Review

Jane Street sold out of Actuate Therapeutics (ACTU) in Q1 2026, closing a stake of 16,625 shares — an estimated $102K sold.

Jane Street first reported a position in ACTU in Q4 2025 and held it in 1 quarter. The position peaked at $102K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

Jane Street reported no remaining Actuate Therapeutics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 16,625 Actuate Therapeutics shares in Q1 2026, an estimated $102K.
Jane Street first reported a position in Actuate Therapeutics in Q4 2025 and held it in 1 quarter.
Jane Street's Actuate Therapeutics position peaked at $102K in Q4 2025.
61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.